Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 44

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Axial spondyloarthritis

Recruiting

Study on Axial Spondyloarthritis Treatment Using Technetium-Labeled Certolizumab Pegol for Patients with Axial Spondyloarthritis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Technetium (99MTC) certolizumab pegol
  • Sponsor:Universitair Ziekenhuis Gent

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study on Long-term Safety and Efficacy of Efgartigimod PH20 SC in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Neonatal alloimmune thrombocytopenia

Recruiting

Study on Nipocalimab for Reducing Risk of Fetal and Neonatal Alloimmune Thrombocytopenia in At-risk Pregnancies

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Crohn's disease

Recruiting

Study on Preventing Crohn's Disease Recurrence After Surgery Using Risankizumab and Drug Combination in Adults at Risk

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:UZ Leuven

Corneal transplant+2

Recruiting

Study on Dexamethasone and Fluorometholone for Patients Undergoing Corneal Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Academisch Ziekenhuis Maastricht

Rheumatoid arthritis

Recruiting

Study on Abatacept for Rheumatoid Arthritis in Patients Responding to Initial TNF Inhibitor Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Psoriasis

Recruiting

Study on Risankizumab for Children Aged 6-17 With Moderate to Severe Plaque Psoriasis After Completing Previous Study

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Type 1 diabetes mellitus

Recruiting

Study on the Effect of Influenza Vaccine on Preserving Beta Cell Function in Early Type 1 Diabetes Patients

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Sponsor:Region Midtjylland

Interstitial lung disease

Recruiting

Study on the Effectiveness and Safety of Rituximab for Patients with Progressive Interstitial Lung Disease with Inflammation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Colitis ulcerative

Recruiting

Study on Etrasimod for Adolescents with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Kidney transplant rejection

Recruiting

Study on Imlifidase and Drug Combination for Kidney Transplant in Highly Sensitized Children

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Imlifidase
  • Sponsor:Hansa Biopharma AB

Sarcoidosis

Recruiting

Study on Hydroxychloroquine and Prednisone for Patients with Non-Severe Extra-Pulmonary Sarcoidosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Hospices Civils De Lyon

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.